Based on the available information, there is evidence to suggest a potential link between the overuse of tigecycline, an antibiotic drug, and worse patient outcomes. The FDA has issued a warning regarding an increased risk of death associated with the intravenous use of tigecycline (also known by its brand name, Tygacil) [3]. This warning was based on the FDA's review of post-marketing studies, which found that tigecycline was associated with a higher all-cause mortality rate compared to other antibiotics [3].

Furthermore, a study published in the Journal of Medical Economics analyzed the relationship between tigecycline utilization and clinical outcomes in patients with complicated intra-abdominal infections [2]. The results of this study showed that tigecycline utilization was associated with a higher risk of treatment failure and mortality compared to other antibiotics [2].

It is important to note that tigecycline has been approved by the FDA for the treatment of certain infections caused by susceptible bacteria, and it remains an important antibiotic option in some cases [1][3]. However, the evidence suggests that the overuse of tigecycline may be linked to worse patient outcomes, and it is crucial for healthcare providers to consider this risk when prescribing this antibiotic.

In summary, based on the available information, there is evidence to suggest a potential link between the overuse of tigecycline and worse patient outcomes. The FDA has issued a warning regarding an increased risk of death associated with the intravenous use of tigecycline, and a study has shown that tigecycline utilization is associated with a higher risk of treatment failure and mortality compared to other antibiotics.

Sources:

1. <https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE>
2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242406/>
3. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline>